Cancer immunotherapeutics specialist immatics raises EUR54m


Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.



Penzberg (Germany) - Diagnostics and IT giants Roche and IBM are joining forces to bring down the cost of DNA sequencing to a few hundred euros. On Thursday, the companies announced that they will develop a nanopore-based DNA...



Berlin – The German Bioethics Council has proposed to establish new rules to secure sensitive personal data stored in biobanks of human specimens. The new rules proposed to be applied internationally foresee the creation of a...



Ingelheim – Just one week after Boehringer Ingelheim GmbH announced Phase III results, which suggested its 5-HT and dopamine D receptor agonist flibanserin boosted sexual desire in women with hypoactive sexual desire disorder,...



Hamburg/Melbourne – Researchers have discovered a new drug target that blocks the malaria parasite from entering human blood cells (PLoSPathog.Jun 3;6(6):e100094). Currently, there is no vaccine against the Plasmodium parasite...



Martinsried/Bethesda – Micromets bifunctional monoclonal antibody drug blinatumomab (MT103) has met its study goals in two independent clinical trails. In a Phase I dose escalation study in 52 adult patients with relapsed...



Tuebingen - German Immatics biotechnologies heaps up partners for it cancer vaccine IMA950. The biotechnology company from Tuebingen announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research...



Martinsried – Researchers from the Max Planck Insitute for Biochemistry have presented a novel technique that enables them to map the entire pattern of N-glycosylation (linking a sugar to the amino acid asparagine) and the...

Displaying results 101 to 110 out of 454

< Previous 101-110 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015

Current issue

All issues